Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, H.W. | - |
dc.contributor.author | Kim, S.-M. | - |
dc.contributor.author | Jung, M.K. | - |
dc.contributor.author | Noh, J.Y. | - |
dc.contributor.author | Yoo, J.-S. | - |
dc.contributor.author | Kim, E.-H. | - |
dc.contributor.author | Kim, Y.-I. | - |
dc.contributor.author | Yu, K. | - |
dc.contributor.author | Jang, S.-G. | - |
dc.contributor.author | Gil, J. | - |
dc.contributor.author | Casel, M.A. | - |
dc.contributor.author | Rare, R. | - |
dc.contributor.author | Choi, J.H. | - |
dc.contributor.author | Kim, H.-S. | - |
dc.contributor.author | Kim, J.H. | - |
dc.contributor.author | Um, J. | - |
dc.contributor.author | Kim, C. | - |
dc.contributor.author | Kim, Y. | - |
dc.contributor.author | Chin, B.S. | - |
dc.contributor.author | Jung, S. | - |
dc.contributor.author | Choi, J.Y. | - |
dc.contributor.author | Song, K.-H. | - |
dc.contributor.author | Kim, Y.-D. | - |
dc.contributor.author | Park, J.-S. | - |
dc.contributor.author | Song, J.Y. | - |
dc.contributor.author | Shin, E.-C. | - |
dc.contributor.author | Choi, Y.K. | - |
dc.date.accessioned | 2022-12-11T11:40:32Z | - |
dc.date.available | 2022-12-11T11:40:32Z | - |
dc.date.created | 2022-12-08 | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 2666-3791 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/146992 | - |
dc.description.abstract | Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern. © 2022 The Author(s) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Cell Press | - |
dc.title | Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Noh, J.Y. | - |
dc.contributor.affiliatedAuthor | Song, J.Y. | - |
dc.identifier.doi | 10.1016/j.xcrm.2022.100764 | - |
dc.identifier.scopusid | 2-s2.0-85139299618 | - |
dc.identifier.bibliographicCitation | Cell Reports Medicine, v.3, no.10 | - |
dc.relation.isPartOf | Cell Reports Medicine | - |
dc.citation.title | Cell Reports Medicine | - |
dc.citation.volume | 3 | - |
dc.citation.number | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | ancestral | - |
dc.subject.keywordAuthor | breakthrough infection | - |
dc.subject.keywordAuthor | cross-neutralization | - |
dc.subject.keywordAuthor | D614G | - |
dc.subject.keywordAuthor | mRNA vaccine | - |
dc.subject.keywordAuthor | Omicron BA.1 | - |
dc.subject.keywordAuthor | Omicron BA.2 | - |
dc.subject.keywordAuthor | recovered patient | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | T cell immune response | - |
dc.subject.keywordAuthor | variants of concern | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.